What are the implications of having three prostate lesions with PI-RADS (Prostate Imaging-Reporting and Data System) scores of 3, 4, and 4, in the context of an elevated Prostate-Specific Antigen (PSA) level?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Your MRI Results Indicate a High Likelihood of Clinically Significant Prostate Cancer and You Should Proceed with Prostate Biopsy

Given your two PI-RADS 4 lesions in the peripheral zone, you have approximately a 70% probability of harboring clinically significant prostate cancer (Gleason score ≥3+4), and biopsy is strongly recommended regardless of your PSA density. 1

Understanding Your PI-RADS Scores

Your MRI identified three lesions with different risk levels:

  • PI-RADS 4 lesions (Lesions #1 and #2): These carry the highest concern. Large validation studies demonstrate that PI-RADS 4-5 lesions are associated with clinically significant cancer in 67-71% of cases. 1 The probability of cancer detection for PI-RADS 4 specifically is approximately 71%. 1

  • PI-RADS 3 lesion (Lesion #3): This represents an equivocal finding with approximately 17-31% probability of clinically significant cancer. 1, 2

Why Biopsy is Necessary in Your Case

Patients with PI-RADS ≥4 lesions should undergo prostate biopsy regardless of PSA density. 3 Your PSA density of 0.07 ng/mL² is actually quite low, but this does not change the recommendation when PI-RADS 4 lesions are present. 3

The evidence is clear on this point:

  • For PI-RADS ≥4 lesions, the clinically significant cancer risk remains ≥40% regardless of PSA density values. 3
  • PI-RADS v2 demonstrates high diagnostic accuracy with 89% sensitivity and 73% specificity for prostate cancer detection. 1, 4
  • The system is specifically designed to identify cancers that matter clinically while avoiding overdiagnosis of indolent disease. 1, 4

What About Your PI-RADS 3 Lesion?

Your larger transition zone lesion (22 mm, PI-RADS 3) presents a different consideration:

  • With your PSA density of 0.07 ng/mL², which is well below the 0.10 ng/ml/cm³ threshold, this lesion alone would not mandate biopsy. 3
  • Using a PSAD cutoff of 0.10 for PI-RADS 3 lesions would save approximately 32% of biopsies while missing only 7% of clinically significant cancers. 3
  • However, since you're proceeding with biopsy due to your PI-RADS 4 lesions, this area should also be sampled. 5

Recommended Biopsy Approach

You should undergo MRI-directed targeted biopsy of all three lesions plus systematic biopsy. 4 This combined approach is critical because:

  • Targeted biopsy alone can miss clinically significant cancer, particularly in PI-RADS 3 lesions. 5
  • In one study of PI-RADS 3 lesions, systematic biopsies detected clinically significant cancer that would have been missed by targeted biopsy alone in multiple patients. 5
  • The European Association of Urology guidelines recommend MRI-directed biopsy plus systematic biopsy for PI-RADS 4-5 lesions in biopsy-naïve patients. 4

Important Caveats

Common pitfall to avoid: Do not be falsely reassured by your low PSA density. While PSA density is valuable for risk stratification in PI-RADS 3 lesions, it does not reduce the cancer probability sufficiently in PI-RADS 4 lesions to avoid biopsy. 3

What the biopsy may show:

  • Your peripheral zone lesions (PI-RADS 4) have the highest concern for Gleason ≥3+4 disease. 1
  • Index lesions with Gleason ≥3+4 pattern and volume ≥0.2 ml (approximately 7-8 mm diameter) are typically identifiable on modern MRI, and both your PI-RADS 4 lesions exceed this size threshold. 1
  • No extraprostatic extension was noted on your MRI, which is favorable if cancer is present. 1

Quality consideration: Your MRI was performed at a high-quality academic center (University of Wisconsin-Madison), which enhances the reliability of these PI-RADS scores. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Probability of Prostate Cancer with PI-RADS 3 Lesions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

PI-RADS Guidelines for Prostate Cancer Detection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.